Вернуться к статье
Monitoring of the Apixaban’s pharmacodynamics in patients with non-valvular atrial fibrillation
Figure 1 - Confidence intervals of 3-day monitoring of apixaban concentration at a dose of 5 mg twice daily in the blood plasma of patients with AFNE